Chronic Treatment with the Probiotics Lacticaseibacillus rhamnosus GG and Bifidobacterium lactis BB12 Attenuates Motor Impairment, Striatal Microglial Activation, and Dopaminergic Loss in Rats with 6-Hydroxydopamine-induced Hemiparkinsonism

[1]  Bangmao Wang,et al.  Lactobacillus rhamnosus GG Colonization in Early Life Ameliorates Inflammaging of Offspring by Activating SIRT1/AMPK/PGC-1α Pathway , 2021, Oxidative Medicine and Cellular Longevity.

[2]  Chieh-Hsi Wu,et al.  Probiotic Supplementation Facilitates Recovery of 6-OHDA-Induced Motor Deficit via Improving Mitochondrial Function and Energy Metabolism , 2021, Frontiers in Aging Neuroscience.

[3]  M. Adeleke,et al.  Multi-Strain Probiotics: Synergy among Isolates Enhances Biological Activities , 2021, Biology.

[4]  B. Gao,et al.  Association of Parkinson’s Disease With Microbes and Microbiological Therapy , 2021, Frontiers in Cellular and Infection Microbiology.

[5]  A. Laguna,et al.  New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota , 2021, Biomolecules.

[6]  H. Salgado,et al.  Chronic feeding with 3% dried raw blueberries (V. corymbosum) reduces apomorphine-induced rotations and striatal dopaminergic loss in hemiparkinsonian rats. , 2021, Food research international.

[7]  Zongxin Ling,et al.  Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson’s disease via gut microbiota-GLP-1 pathway , 2020, Brain, Behavior, and Immunity.

[8]  M. Taghizadeh,et al.  Neuroprotective effects of probiotics bacteria on animal model of Parkinson’s disease induced by 6-hydroxydopamine: A behavioral, biochemical, and histological study , 2020, Journal of immunoassay & immunochemistry.

[9]  A. Cimini,et al.  The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson’s disease? , 2020, Neural regeneration research.

[10]  G. Savoy de Giori,et al.  Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson's disease model. , 2020, Nutrition.

[11]  Ying-Zu Huang,et al.  Probiotics Alleviate the Progressive Deterioration of Motor Functions in a Mouse Model of Parkinson’s Disease , 2020, Brain sciences.

[12]  A. Giordano,et al.  Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models , 2020, Aging.

[13]  J. Baizabal-Carvallo,et al.  The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease , 2020, Neuroscience.

[14]  Jikai Wen,et al.  Lactobacillus rhamnosus GG supplementation modulates the gut microbiota to promote butyrate production, protecting against deoxynivalenol exposure in nude mice. , 2020, Biochemical pharmacology.

[15]  D. Frenkel,et al.  Microglia and Parkinson's disease: footprints to pathology , 2020, Journal of Neural Transmission.

[16]  Y. Tizabi,et al.  Differential Effects of LPS and 6-OHDA on Microglia’s Morphology in Rats: Implications for Inflammatory Model of Parkinson’s Disease , 2019, Neurotoxicity Research.

[17]  P. Gazerani.  Probiotics for Parkinson’s Disease , 2019, International journal of molecular sciences.

[18]  J. Hong,et al.  Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. , 2019, The Journal of nutritional biochemistry.

[19]  B. Neves,et al.  The Gut and Parkinson's Disease—A Bidirectional Pathway , 2019, Front. Neurol..

[20]  M. Taghizadeh,et al.  Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. , 2019, Clinical nutrition.

[21]  B. Bloem,et al.  The Emerging Evidence of the Parkinson Pandemic , 2018, Journal of Parkinson's disease.

[22]  R. Liddle.  Parkinson’s disease from the gut , 2018, Brain Research.

[23]  G. Rossi,et al.  SLAB51 Probiotic Formulation Activates SIRT1 Pathway Promoting Antioxidant and Neuroprotective Effects in an AD Mouse Model , 2018, Molecular Neurobiology.

[24]  P. Brundin,et al.  The concept of alpha-synuclein as a prion-like protein: ten years after , 2018, Cell and Tissue Research.

[25]  D. Perani,et al.  Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease , 2017, NeuroImage: Clinical.

[26]  C. Braun,et al.  Effect of Probiotics on Central Nervous System Functions in Animals and Humans: A Systematic Review , 2016, Journal of neurogastroenterology and motility.

[27]  Sumit Sarkar,et al.  Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives , 2016, International journal of molecular sciences.

[28]  W. Lei,et al.  Characteristic Changes of Astrocyte and Microglia in Rat Striatum Induced by 3-NP and MCAO , 2016, Neurochemical Research.

[29]  R. Burke,et al.  Retrograde Axonal Degeneration in Parkinson Disease , 2016, Journal of Parkinson's disease.

[30]  H. Braak,et al.  Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathology , 2016, Neuropathology and applied neurobiology.

[31]  Muralidhara,et al.  Probiotic attributes, antioxidant, anti-inflammatory and neuromodulatory effects of Enterococcus faecium CFR 3003: in vitro and in vivo evidence. , 2015, Journal of medical microbiology.

[32]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[33]  A. Pastor,et al.  Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context , 2015, Front. Cell. Neurosci..

[34]  Glenn R. Gibson,et al.  The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .

[35]  Meijiang Feng,et al.  The Expression and Release of Hsp60 in 6-OHDA Induced In Vivo and In Vitro Models of Parkinson’s Disease , 2013, Neurochemical Research.

[36]  Juliet M. Taylor,et al.  Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease , 2013, Neurochemistry International.

[37]  S. Duty,et al.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease , 2011, British journal of pharmacology.

[38]  K. Takata,et al.  The 6‐hydroxydopamine‐induced nigrostriatal neurodegeneration produces microglia‐like NG2 glial cells in the rat substantia nigra , 2010, Glia.

[39]  D. Pemberton,et al.  Alternative method of oral dosing for rats. , 2010, Journal of the American Association for Laboratory Animal Science : JAALAS.

[40]  O. Gokce,et al.  Short-Term Striatal Gene Expression Responses to Brain-Derived Neurotrophic Factor Are Dependent on MEK and ERK Activation , 2009, PloS one.

[41]  J. L. Bata-García,et al.  Sustained improvement of motor function in hemiparkinsonian rats chronically treated with low doses of caffeine or trihexyphenidyl , 2007, Pharmacology Biochemistry and Behavior.

[42]  J. Henderson,et al.  Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease , 2007, Journal of Neuroscience Methods.

[43]  Y. Michotte,et al.  Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease , 2005, Journal of Neuroscience Methods.

[44]  D. Dexter,et al.  Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease , 2004, Pharmacology Biochemistry and Behavior.

[45]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[46]  Y. Imai,et al.  Intracellular signaling in M‐CSF‐induced microglia activation: Role of Iba1 , 2002, Glia.

[47]  O. Isacson,et al.  Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging , 2002, The European journal of neuroscience.

[48]  Xuechu Zhen,et al.  Activation of Extracellular Signal-Regulated Protein Kinases Is Associated with a Sensitized Locomotor Response to D2Dopamine Receptor Stimulation in Unilateral 6-Hydroxydopamine-Lesioned Rats , 2000, The Journal of Neuroscience.

[49]  J. P. Huston,et al.  The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.

[50]  D. Togasaki,et al.  Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.

[51]  S. Wiegand,et al.  Efficacy of Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 on Neurochemical and Behavioral Deficits Associated with Partial Nigrostriatal Dopamine Lesions , 1994, Journal of neurochemistry.

[52]  D J Woodward,et al.  A region in the dorsolateral striatum of the rat exhibiting single-unit correlations with specific locomotor limb movements. , 1990, Journal of neurophysiology.

[53]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence , 1989, Brain Research.

[54]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[55]  Jean-Christophe Rochet,et al.  Molecular insights into Parkinson's disease. , 2012, Progress in molecular biology and translational science.

[56]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.